Reprogramming T Cells to Cross the Brain’s Border

Episode Summary

Executive Summary: The episode features Adaptin Bio CEO Michael Roberts explaining how the company is trying to overcome glioblastoma’s fatal biology and the blood-brain barrier by using patient-derived T cells as delivery vehicles for bispecific biologics. The discussion covers the unmet need in GBM, why existing BBB-crossing methods fall short, the BRITE platform, lead program APTN 101, early preclinical and safety signals, and the company’s financing and development plans.

Main Topics: Glioblastoma’s biology and unmet need (Priority: 5/5): Roberts describes GBM as a grade 4 astrocytoma with rapid growth, diffuse infiltration, and high heterogeneity, which makes it difficult to diagnose early and nearly impossible to treat effectively with single-agent approaches. Why the blood-brain barrier blocks progress (Priority: 5/5): The conversation emphasizes that the BBB protects the brain but also prevents adequate drug delivery, explaining why standard surgery, radiation, and chemotherapy have not substantially improved survival. Limitations of current BBB-crossing strategies (Priority: 4/5): Roberts reviews direct injection, convection-enhanced delivery, intrathecal dosing, focused ultrasound/microbubbles, receptor-mediated transcytosis, and nanoparticles, arguing each has major drawbacks such as invasiveness, poor distribution, or limited controllability. BRITE platform mechanism (Priority: 5/5): Adaptin’s BRITE platform uses patient T cells as a carrier to transport bispecific T-cell engagers across the BBB and into target tissue, where the engager links the T cell to the tumor cell and triggers killing. Lead program APTN 101 (Priority: 5/5): APTN 101 pairs manipulated patient T cells with a bispecific antibody targeting EGFRvIII and CD3, delivered by IV infusion over several days to broadly reach diffuse brain disease. Preclinical data and safety outlook (Priority: 4/5): Roberts cites preclinical evidence of more than sevenfold increased brain delivery of large proteins and 70%–80% long-term survival in mouse GBM models, alongside safety studies suggesting limited off-target toxicity. Corporate strategy, financing, and pipeline expansion (Priority: 4/5): The company plans a Phase 1 trial in early 2026, is pursuing public-market access through a reverse-merger/OTC process, and wants to expand beyond GBM into brain metastases and neurodegenerative diseases.

Key Arguments: GBM remains largely refractory to current therapy because it is highly heterogeneous and because the BBB prevents sufficient drug exposure in the brain. Existing BBB-opening or BBB-bypassing methods are either invasive, localized, or insufficiently controllable for a diffuse disease like GBM. Using a patient’s own T cells as a delivery vehicle may solve two problems at once: transporting the payload across the BBB and adding immune effector cells to a typically “cold” tumor microenvironment. The BRITE platform is intended to be modular; while lead assets focus on T-cell engagers, the carrier concept could potentially be adapted to antibodies, oligonucleotides, and other payloads. APTN 101 is designed for high specificity by targeting EGFRvIII, a tumor-associated antigen, which may reduce off-target toxicity. The company believes its manufacturing approach is simpler and cheaper than fully genetically engineered cell therapies because it avoids viral vectors and complex ex vivo engineering. Adaptin’s strategic focus is to build its own CNS pipeline while remaining open to partnerships that can accelerate clinical development and commercialization.

Data Points: GBM grade: Grade 4 astrocytoma - Roberts explains glioblastoma is the highest malignancy stage and already advanced at diagnosis. Typical survival after standard-of-care treatment: Less than 24 months - Reported for patients after resection, radiotherapy, and chemotherapy. Survival after recurrence: About 8 months - Roberts describes the prognosis once GBM returns. Brain delivery improvement: More than 7-fold - Preclinical studies showed increased distribution of large proteins like T-cell engagers into the brain. Long-term survival in mouse models: 70%–80% - Observed in preclinical GBM mouse studies using the BRITE approach. Annual U.S. GBM diagnoses: About 15,000 patients - Roberts cites the size of the primary GBM population in the U.S. HER2-positive breast cancer brain metastasis mortality share: About 30% - Used to illustrate the potential market for treating brain metastases. Reverse-merger financing raised: About $7.7 million - Capital raised in the transaction with Unite Acquisition One Corporation. Phase 1 timing: First quarter of 2026 - Expected initiation of the GBM phase 1 safety trial. Infusion duration: Four-day period - APTN 101 is administered by IV infusion over several days to maintain therapeutic levels.

Pivotal Quotes: "Mother Nature put in a thing called the blood-brain barrier" — Michael Roberts: Explaining why delivering therapeutics to the brain is inherently difficult. "If we not have the delivery vehicle in the brain at the tumor microenvironment, the T cell engager alone would not likely be highly effective." — Michael Roberts: Describing why the carrier T cells are essential to the platform’s activity. "Our technology is able to change as the tumor changes." — Michael Roberts: Positioning the platform as adaptable against GBM’s evolving biology.

Implications: If Adaptin’s approach translates clinically, it could reshape CNS drug delivery by combining transport and therapy in one platform. Success in GBM would validate expansion into brain metastases and neurodegenerative disease, while also making the company more attractive for partnering and financing.